Abemaciclib

About

Therapy type: Targeted therapy

Therapy strategy: CDK4/6 inhibition

Mappings

NCI Thesaurus: Abemaciclib (coding:ncit:C97660)

RxNorm: abemaciclib (coding:rxcui:1946825, coding:omop:792649)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
EMA (1) FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Tamoxifen
EMA (1) FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen
EMA (1) FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen
EMA (2) FDA (4) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Anastrozole
EMA (2) FDA (4) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole
EMA (2) FDA (4) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole
EMA (2) FDA (4) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Letrozole
EMA (2) FDA (4) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole
EMA (2) FDA (4) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole
EMA (1) FDA (4) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Fulvestrant
EMA (1) FDA (4) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant
EMA (1) FDA (4) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant
FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib
FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib
FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib
EMA (1) FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane
EMA (1) FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Exemestane
EMA (1) FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane
EMA (1) ER positive, ESR1 activating variants, HER2-negative Invasive Breast Carcinoma Abemaciclib, Camizestrant